Background: Transgender healthcare is not a formal learning requirement in Internal Medicine residency or fellowship. The National LGBTQ Task Force appealed to urgently train clinicians on the effective care of transg...Background: Transgender healthcare is not a formal learning requirement in Internal Medicine residency or fellowship. The National LGBTQ Task Force appealed to urgently train clinicians on the effective care of transgender patients. Few studies address the successful implementation of transgender healthcare teaching and education in graduate medical education. Purpose: The purpose was to design an online asynchronous curriculum to address the need for improved transgender healthcare education in graduate medical education and assess change in knowledge and comfort in transgender healthcare for residents and fellow learners. Methods: A 6-module curriculum was developed using established guidelines and ACGME competencies as a framework for content. To assess curriculum effectiveness, participants received anonymous pre- and post-curriculum surveys which included a multiple-choice knowledge assessment, Likert scale comfort questions focusing on healthcare skills, and open-ended feedback questions. Results: Twenty-six internal medicine residents and fellows participated in the curriculum (2022-2023). There was a 69% post-survey response rate. Participants improved their gender-affirming knowledge after completing the curriculum (p Conclusion: This online curriculum was successful in increasing knowledge and comfort in transgender care for IM residents and fellows. It provides a promising framework to address this gap in curricular content.展开更多
二肽基肽酶-4(dipeptidyl-peptidase-4,DPP-4)抑制剂是糖尿病药物治疗领域的突破。目前国内已上市的5种DPP-4抑制剂,包括有西格列汀、维格列汀、沙格列汀、利格列汀和阿格列汀。本文从疗效、安全性、特殊人群中的应用及降糖外作用等方...二肽基肽酶-4(dipeptidyl-peptidase-4,DPP-4)抑制剂是糖尿病药物治疗领域的突破。目前国内已上市的5种DPP-4抑制剂,包括有西格列汀、维格列汀、沙格列汀、利格列汀和阿格列汀。本文从疗效、安全性、特殊人群中的应用及降糖外作用等方面对此类药物进行阐述和差异比较,对DPP-4抑制剂在临床的药物应用选择有重要的指导意义。在获得Expert Opinion on Pharmacotherapy杂志(Taylor&Francis Group)授权同意后,本文对2017年5月发表于该刊上的社论"DPP-4抑制剂类药物在2型糖尿病管理中的应用比较与选择"进行中文编译,并特邀山东大学齐鲁医院内分泌科陈丽教授对文稿进行点评。展开更多
文摘Background: Transgender healthcare is not a formal learning requirement in Internal Medicine residency or fellowship. The National LGBTQ Task Force appealed to urgently train clinicians on the effective care of transgender patients. Few studies address the successful implementation of transgender healthcare teaching and education in graduate medical education. Purpose: The purpose was to design an online asynchronous curriculum to address the need for improved transgender healthcare education in graduate medical education and assess change in knowledge and comfort in transgender healthcare for residents and fellow learners. Methods: A 6-module curriculum was developed using established guidelines and ACGME competencies as a framework for content. To assess curriculum effectiveness, participants received anonymous pre- and post-curriculum surveys which included a multiple-choice knowledge assessment, Likert scale comfort questions focusing on healthcare skills, and open-ended feedback questions. Results: Twenty-six internal medicine residents and fellows participated in the curriculum (2022-2023). There was a 69% post-survey response rate. Participants improved their gender-affirming knowledge after completing the curriculum (p Conclusion: This online curriculum was successful in increasing knowledge and comfort in transgender care for IM residents and fellows. It provides a promising framework to address this gap in curricular content.
文摘二肽基肽酶-4(dipeptidyl-peptidase-4,DPP-4)抑制剂是糖尿病药物治疗领域的突破。目前国内已上市的5种DPP-4抑制剂,包括有西格列汀、维格列汀、沙格列汀、利格列汀和阿格列汀。本文从疗效、安全性、特殊人群中的应用及降糖外作用等方面对此类药物进行阐述和差异比较,对DPP-4抑制剂在临床的药物应用选择有重要的指导意义。在获得Expert Opinion on Pharmacotherapy杂志(Taylor&Francis Group)授权同意后,本文对2017年5月发表于该刊上的社论"DPP-4抑制剂类药物在2型糖尿病管理中的应用比较与选择"进行中文编译,并特邀山东大学齐鲁医院内分泌科陈丽教授对文稿进行点评。
